Miriplatin

Miriplatin (INN; trade name Miripla) is a drug used to treat hepatocellular carcinoma (HCC). It is a lipophilic platinum complex that is used in transcatheter arterial chemoembolization (TACE).^[1][2] Miriplatin was approved by Japan's Pharmaceuticals and Medical Devices Agency in 2009.^[1]

Miriplatin

Clinical data
Trade names	Miripla
Legal status
Legal status	Rx in Japan
Identifiers
IUPAC name Cyclohexane-(1R,2R)-diamineplatinum(II) dimyristate
CAS Number	141977-79-9
PubChem CID	9832045
ChemSpider	8007775
UNII	780F0P8N4I
KEGG	D06294
Chemical and physical data
Formula	C34H68N2O4Pt
Molar mass	764.012 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCC(=O)[O-].C1CC[C@]([H])([C@@]([H])(C1)N)N.[Pt+2]
InChI InChI=1S/2C14H28O2.C6H14N2.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;/q;;;+2/p-2/t;;5-,6-;/m..1./s1 Key:BGIHRZPJIYJKAZ-BLUNCNMSSA-L

See also

• Oxaliplatin

References

1. "Miriplatin". Inxight Drugs. National Center for Advancing Translational Sciences, National Institutes of Health.
2. Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, et al. (February 2018). "Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial". Journal of Gastroenterology. 53 (2): 281–290. doi:10.1007/s00535-017-1374-6. PMC 5846877. PMID 28766016.

External links

• Development of Miriplatin, a Novel Antitumor Platinum for Hepatocellular Carcinoma